Leap therapeutics to present new clinical data from part a of defiance study at the 2024 asco gastrointestinal cancers symposium

30% orr and 93% dcr across heterogenous second-line crc patients treated with dkn-01 plus bevacizumab and chemotherapy subgroup analysis reveals greatest benefit in left-sided tumors, particularly rectal and rectosigmoid patients with 46% orr, 100% dcr, and preliminary median pfs of 9.4 months. leap to host conference call to report additional clinical data including further subgroup analyses on tuesday, january 23, 2024 at 8:30 a.m.
LPTX Ratings Summary
LPTX Quant Ranking